Lek, a Sandoz company in the news

Sandoz opened a 400 million euro high-tech center in Lendava, Slovenia, for large-scale biosimilar active ingredient production, creating over 300 jobs as part of a 1.3 billion euro investment cycle in the country.

Lek, a Sandoz company, opened a 400 million euro high-tech Biopharmaceutical center in Lendava for biosimilar active ingredient production, marking its largest investment and one of Slovenia's biggest foreign direct investments.

Sandoz opened a high-tech center in Lendava, Slovenia, for biosimilar medicine production, creating over 300 jobs and marking a significant investment in expanding its European manufacturing network and biosimilar portfolio.

Sandoz, including Lek, saw a nine percent increase in net sales in Q2, despite a reported profit drop, leading to a rise in stock price.

Sandoz has inaugurated a $99 million biosimilar development center in Ljubljana, marking the start of a planned $1 billion investment cycle in Slovenia through 2029.

Lek, a Sandoz company, opened a 90 million euro biosimilar development center in Ljubljana, Slovenia.

Lek has opened a new 90 million euro pharmaceutical development centre in Ljubljana.

Sandoz has requested an EU anti-dumping investigation into Chinese antibiotic ingredients to protect European production sites, including Lek's operations in Slovenia.

Construction of a new 350 million euro biopharmaceutical center in Lendava is creating over 300 jobs and new academic partnerships.

A 350 million euro biopharmaceutical production facility is being built in Lendava to manufacture biosimilar active ingredients and create 370 new jobs.

A 350 million euro investment in Lendava for a new biosimilar production facility and quality control lab is creating 370 new jobs.

Lek is constructing a 541.8 million euro biosimilar production facility in Lendava while reducing its reliance on government subsidies.

Slovenia is providing up to 42 million euro in grants to Lek, a Sandoz company, for a new high-tech biosimilar production plant in Lendava.

Lek is hosting a biotechnology and AI research event in collaboration with the University of Ljubljana to foster industry-academic partnerships.

Lek is distributing 100 million euros in profit to Sandoz while investing over 1 billion euros in Slovenian biosimilar production and development facilities.

Lek reported significant workforce growth with strong training programs, improved workplace safety, and committed environmental sustainability efforts in its 2024 sustainability report.

Lek has started constructing a 400 million euro biosimilars factory in Brnik.

Lek is investing 400 million euros in a new high-tech biosimilar manufacturing facility at Brnik, creating 250 jobs.

Lek has commenced building a 400 million euro biosimilars manufacturing plant in Brnik, Slovenia.

Sandoz is investing 400 million euros in a new biosimilar production facility in Brnik as part of a larger 1 billion euro investment plan in Slovenia.